XOMA Royalty (XOMA) Minority Interest (2024 - 2026)

XOMA Royalty (XOMA) reported Minority Interest of $20.0 million for Q1 2026, little changed sequentially from $20.0 million in Q4 2025.

XOMA Royalty (XOMA) Minority Interest (2024 - 2026) Analysis & Trends

XOMA Royalty (XOMA) has 3 years of Minority Interest data on file, last reported at $20.0 million in Q1 2026.

For the quarter ending Q1 2026, Minority Interest changed N/A year-over-year to $20.0 million; the trailing twelve-month figure through Mar 2026 stood at $20.0 million (changed N/A YoY), and the FY2025 full-year result was $20.0 million, changed 0.0% from the prior year.
Minority Interest held at $20.0 million in Q1 2026, from $20.0 million in the prior quarter.
In the past five years, Minority Interest ranged from a high of $20.0 million in Q4 2024 to a low of $20.0 million in Q4 2024.
A 3-year average of $20.0 million and a median of $20.0 million in 2024 frame the typical range for Minority Interest.
Peak annual rise in Minority Interest reached 0.0% in 2025, while the deepest fall reached 0.0% in 2025.
Tracing XOMA's Minority Interest over 3 years: stood at $20.0 million in 2024, then changed by 0.0% to $20.0 million in 2025, then changed by 0.0% to $20.0 million in 2026.
Business Quant data shows XOMA's Minority Interest at $20.0 million in Q1 2026, $20.0 million in Q4 2025, and $20.0 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	XOMA Royalty	478.42 Mn	412.34 Mn	-

Download Data